Akeso Advances NSCLC Combination Therapy into Phase II Trials
Event summary
- Akeso dosed the first patient in a Phase II study of AK146D1 (TROP2/Nectin-4 bispecific ADC) combined with ivonescimab for advanced NSCLC.
- The trial focuses on first-line treatment, a strategically important setting for lung cancer therapy.
- AK146D1 and AK138D1 are key components of Akeso's 'IO2.0 + ADC2.0' strategy.
- Akeso claims to be the only company with two approved bispecific antibodies for cancer immunotherapy.
The big picture
Akeso's advancement of its ADC2.0 candidates into Phase II trials underscores a strategic push toward next-generation cancer therapies. The combination approach with ivonescimab aligns with industry trends favoring multi-modal treatments for complex diseases like NSCLC. With two approved bispecific antibodies and a robust pipeline, Akeso is positioning itself as a key player in the evolving immuno-oncology landscape.
What we're watching
- Combination Therapy Efficacy
- Whether the AK146D1 and ivonescimab combination can demonstrate superior efficacy in first-line NSCLC treatment.
- ADC2.0 Differentiation
- The pace at which Akeso's next-generation ADC candidates can overcome conventional ADC limitations.
- Global Market Positioning
- How Akeso leverages its bispecific antibody leadership to gain competitive advantages in the global oncology market.